Today, Pharm Aid is the leading supplier of rotavirus vaccine in Russia. It plans to launch the production of a meningococcal vaccine, a vaccine for the prevention of human papillomavirus, and a varicella vaccine.
ensuring we execute our actions responsibly towards each of our following stakeholders:
Patients and health care professionals
We also work with numerous distribution partners, maintaining end-to-end stability throughout the supply chain and thereby fulfilling our commitment to the availability and highest quality of our products.
Board of Directors
Deputy Director General for Economics
Deputy Director General for Construction
Deputy General Director for Development and Production
Head of Project Department
Deputy Director General for Legal Issues
Pharm Aid is an ambitious progressive pharmaceutical company established in 2017 as a joint venture between Ishvan Pharmaceuticals Ltd and independent directors. We are well set on our path to be a leading regional research and development center and a full-cycle producer for multiple novel and emerging vaccines and immuno-biopharmaceutical therapies. As a result, we are playing a pivotal role in the development and modernization of the national pharmaceutical industry in accordance with the Russian Federation’s strategy to achieve indigenization and self-reliance in vaccines and essential drugs.
Despite being a fledgling company, we are a dynamic organization constantly in pursuit of progress, with our sights firmly set on our fundamental motivation – a desire to improve access to best-in-class treatment options for Russia and the CIS, touching the lives of all who use our products.
Compelled by the belief that ‘alone we can do so little, together we can do so much’ and recognizing the disparity in locally available, affordable treatment options, we have set ourselves on a mission to bridge this gap through partnering with the world’s best biopharmaceutical institutions to bring in innovative products and technology.
We are in the process of establishing a modern biopharmaceutical R&D and production complex in Russia, offering the country its first and largest full-cycle, fully-integrated recombinant, live and inactivated viral and bacterial vaccine and antibody development and manufacturing facility. Pharm Aid will produce a wide range of innovative multi-component products developed and manufactured in the country via technology and IP in-licensed from our partners who are pioneers in this sphere.
Alongside the success of our partnerships and our responsibility to fostering Russia’s self-reliance in immunobiological therapies and other critical treatment needs, we also aspire to be a leading global hub for research and innovation. We plan to expand our influence across multiple emerging biopharmaceutical therapy areas, as well as in the domains of medical devices, novel diagnostics, and other priorities that affect a positive health outcome.
OUR PRODUCT PIPELINE
Inside our bespoke, high-tech facility, our approach to R&D ism to combine the best practices available in Russian and global biotechnology companies to increase the accessibility of quality treatments for the population of Russia.
Drawing on local and international expertise across the entire spectrum of the research, development and commercialization value chain allows us to deliver on this mission and develop and produce new sustainable and affordable drugs domestically, providing significant financial savings for the Federal healthcare budget in Russia.
OUR APPROACH TO SUSTAINABILITY
OUR PRODUCT PIPELINE
OUR PATIENTS AND PRESCRIBERS
We in-license product and process technology, and Intellectual Property from the world’s best so we are equipped to introduce innovative and affordable drugs and therapies into the market faster.
We also work with numerous channel partners and maintain end-to-end supply chain integrity as part of our commitment to accessibility and quality.
OUR INVESTORS AND SHAREHOLDERS
We understand that good health can’t wait. We are responsible for providing access to innovative treatment options at an affordable price to ensure that federal budgets and out-of-pocket expenses are spent well. For our shareholders who have invested in our mission, this purpose precedes profits.
We are committed to upholding the trust extended to us. We maintain the utmost operational integrity and transparency, sharing up-to date information on the company and its performance to enable our investors and shareholders to make informed decisions.
Pharm Aid’s corporate culture aims to foster a goal-oriented and results-oriented atmosphere of mutual support and integrity.
Our core values:
- We share responsibility
- We promote innovation;
- We are meticulous and professional in our planning and execution;
- We encourage trust and mutual respect.